SCHEMBL3142689

SCHEMBL3142689

Cc1ccc(S(=O)(=O)c2nc(N)nc3c2CCCc2cccnc2-3)cc1

nearest known ligand 0.49

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
KMT2A Q03164 2/20 0.49
ALDH1A1 P00352 6/20 0.41
PAX8 Q06710 1/20 0.41
HSP90AA1 P07900 1/20 0.38
COMT P21964 2/20 0.37
CYP2C19 P33261 2/20 0.36
HTR1A P08908 1/20 0.35
HTR2A P28223 1/20 0.35
HTR7 P34969 1/20 0.35
HTR6 P50406 1/20 0.35
LMNA P02545 3/20 0.35
TDP1 Q9NUW8 3/20 0.35
MAPT P10636 2/20 0.35
HTT P42858 2/20 0.35
KDM4E B2RXH2 2/20 0.35
SMN1; SMN2 Q16637 1/20 0.35
L3MBTL1 Q9Y468 1/20 0.35
MITF O75030 1/20 0.35
S1PR4 O95977 1/20 0.35
S1PR1 P21453 1/20 0.35

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL3144155 0.72 HRH4 (0.38) ALDH1A1KDM4EHRH2HRH3
SCHEMBL3143424 0.72 ALDH1A1 (0.39) KMT2AALDH1A1HSP90AA1CYP2C19LMNA
SCHEMBL3137557 0.71 TDP1 (0.38) KMT2AALDH1A1PAX8HSP90AA1CYP2C19
SCHEMBL3143289 0.71 CA1 (0.46) KMT2AALDH1A1HSP90AA1LMNATDP1
SCHEMBL3131512 0.68 HRH4 (0.60) HRH2HRH3
SCHEMBL1015089 0.67 KMT2A (1.00) KMT2AALDH1A1PAX8HSP90AA1COMT
SCHEMBL4878240 0.67 HRH4 (0.52) ALDH1A1MAPTKDM4ENPSR1HRH2
SCHEMBL13694354 0.67 KMT2A (0.71) KMT2AALDH1A1PAX8COMTCYP2C19
SCHEMBL2166315 0.67 ALDH1A1 (0.49) KMT2AALDH1A1CYP2C19MAPTKDM4E
SCHEMBL1104632 0.66 ALDH1A1 (0.67) KMT2AALDH1A1PAX8HSP90AA1CYP2C19

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-8546410-B2 Heteroaryl-fused macrocyclic pyrimidine derivatives ABBVIE INC. (US) 2013-10-01 US disclosed
US-20100004256-A1 HETEROARYL-FUSED MACROCYCLIC PYRIMIDINE DERIVATIVES ABBOTT LABORATORIES (US) 2010-01-07 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20100004256-A1 HETEROARYL-FUSED MACROCYCLIC PYRIMIDINE DERIVATIVES CDK2, DPYD, CCNB1 KMT2A 2254/4885ALDH1A1 247/4885PAX8 4476/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.